Wilmington Savings Fund Society FSB Has $1.53 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Wilmington Savings Fund Society FSB raised its position in shares of Boston Scientific Co. (NYSE:BSX) by 21.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 17,087 shares of the medical equipment provider’s stock after acquiring an additional 3,069 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Boston Scientific were worth $1,526,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of BSX. Global Wealth Strategies & Associates grew its stake in Boston Scientific by 423.7% during the fourth quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 250 shares during the period. West Oak Capital LLC bought a new position in shares of Boston Scientific during the 4th quarter worth approximately $29,000. Dunhill Financial LLC grew its position in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 152 shares during the period. Values First Advisors Inc. bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $28,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new position in Boston Scientific during the third quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares in the company, valued at approximately $3,610,038.74. This represents a 11.02 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total value of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares in the company, valued at $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 47,302 shares of company stock valued at $4,464,725. Company insiders own 0.50% of the company’s stock.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of research reports. Mizuho raised their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, October 24th. Stifel Nicolaus upped their price target on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research note on Thursday. Canaccord Genuity Group upped their target price on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Finally, Bank of America lifted their price target on shares of Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. One equities research analyst has rated the stock with a hold rating, twenty-two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and a consensus target price of $106.00.

Boston Scientific Trading Up 0.3 %

NYSE BSX opened at $105.33 on Monday. The business’s fifty day moving average is $94.88 and its 200-day moving average is $87.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The stock has a market capitalization of $155.24 billion, a price-to-earnings ratio of 84.26, a PEG ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a one year low of $64.39 and a one year high of $107.17.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Equities research analysts predict that Boston Scientific Co. will post 2.83 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.